The mucopolysaccharidoses (MPS) are a group of rare, inherited lysosomal storage disorders in which accumulation of glycosaminoglycans (GAGs) leads to progressive tissue and organ dysfunction. In addition to a variety of somatic signs and symptoms, patients with rapidly progressing MPS I (Hurler), II, III, and VII can present with significant neurological manifestations, including impaired cognitive abilities, difficulties in language and speech, behavioral abnormalities, sleep problems, and/or seizures. Neurological symptoms have a substantial impact on the quality of life of MPS patients and their families. Due to the progressive nature of cognitive impairment in these MPS patients, neurocognitive function is a sensitive indicator of disease progression, and a relevant outcome when testing efficacy of therapies for these disorders. In order to effectively manage and develop therapies that address neurological manifestations of MPS, it is important to use appropriate neurocognitive assessment tools that are sensitive to changes in neurocognitive function in MPS patients. This review discusses expert opinions on key issues and considerations for effective neurocognitive testing in MPS patients. In addition, it describes the neurocognitive assessment tools that have been used in clinical practice for these patients. The content of this review is based on existing literature and information from a meeting of international experts with extensive experience in managing and treating MPS disorders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ymgme.2017.09.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New generation low level laser effect on masseter muscle oxygenation, bite force and algometric changes in myofacial pain syndrome: a randomised, placebo-controlled clinical trial.
Lasers Med Sci
January 2025
University of Zurich, Zurich, Switzerland.
The aim of this study was to compare the effectiveness of different types of low level laser treatment (LLLT) in reducing pain levels, changing oxygen saturation and bite force in patients with myofacial pain syndrome (MPS). 45 patients were randomly assigned to three groups: Group 1 (GRR laser, n = 15) received LLLT with Gallium-Aluminium-Arsenide (GaAlAs) diode laser with a wavelength of 904 nm and red laser with a wavelength of 650 nm over masseter muscle region. Group 2 (Nd: YAG laser, n = 15) were treated with Neodymium-doped Yttrium Aluminium Garnet laser with a wavelength of 1064 nm and the same protocol with Nd: YAG laser was performed in the Group 3 (placebo, n = 15) using sham device.
View Article and Find Full Text PDFAnti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International Study.
Dig Dis Sci
January 2025
INFINY Institute, Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Université de Lorraine, 54500 , Vandœuvre-lès-Nancy, France.
Background: Therapeutic drug monitoring is important for optimizing anti-tumor necrosis factor-α (TNF-α) therapy in inflammatory bowel disease. However, the exposure-response relationship has never been assessed in pouchitis.
Aims: To explore associations between anti-TNF-α drug concentration and pouchitis disease activity in patients with a background of ulcerative colitis.
D1 dopamine receptor antagonists as a new therapeutic strategy to treat autistic-like behaviours in lysosomal storage disorders.
Mol Psychiatry
January 2025
Telethon Institute of Genetics and Medicine, Via Campi Flegrei 34, Pozzuoli, 80078, Naples, Italy.
Lysosomal storage disorders characterized by defective heparan sulfate (HS) degradation, such as Mucopolysaccharidosis type IIIA-D (MPS-IIIA-D), result in neurodegeneration and dementia in children. However, dementia is preceded by severe autistic-like behaviours (ALBs), presenting as hyperactivity, stereotypies, social interaction deficits, and sleep disturbances. The absence of experimental studies on ALBs' mechanisms in MPS-III has led clinicians to adopt symptomatic treatments, such as antipsychotics, which are used for non-genetic neuropsychiatric disorders.
View Article and Find Full Text PDFParental perception of treatment options for mucopolysaccharidosis: a survey to bridge the gap for personalized medicine.
Orphanet J Rare Dis
January 2025
Institute for Inherited Metabolic Disorders, Paracelsus Medical University Salzburg, 5020, Salzburg, Austria.
Background: Mucopolysaccharidosis (MPS) are a group of lysosomal storage diseases with substantial unmet medical needs-for both patients and caregivers. Approved therapies are limited, and the perception of investigative ones remains enigmatic.
Method: Using an innovative survey concept based on the discrete choice experiment method (DEC) with neuronopathic and non-neuronopathic patient scenarios, we aimed to evaluate how parents of children with MPS perceive different approved and innovative therapies.
Detection of fungal pathogens by a histomolecular approach using targeted-massive parallel sequencing on formalin-fixed tissues: a retrospective study.
Clin Microbiol Infect
January 2025
Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Sud Charles Mérieux, UR 3738 - CICLY - Equipe Inflammation et immunité de l'épithélium respiratoire, Lyon, France; Hospices Civils de Lyon, Hôpital Croix-Rousse, Institut des Agents Infectieux, Service de Parasitologie et Mycologie Médicale, Lyon, France; Hospices Civils de Lyon, Hôpital Croix-Rousse, Institut des Agents Infectieux, Génomique épidémiologique des maladies infectieuses (GENEPII), Lyon, France; Université Claude Bernard Lyon-1, Faculté de Médecine Lyon Est, Lyon, France.
Objectives: Since fungal infections (FI) are frequently encountered by pathologists, it is crucial to improve fungal diagnosis on formalin-fixed paraffin-embedded tissues (FT). We aimed to investigate if a histomolecular approach using targeted-massive parallel sequencing (MPS) could help detect and identify fungi on FT, when no mycological diagnosis is available on fresh tissue.
Methods: Forty-nine FT from 48 patients with histopathological FI diagnosis but without mycological identification were retrospectively included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!